Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload

Deferasirox (DFX) monotherapy is effective for reducing myocardial and liver iron concentrations (LIC), although some patients may require intensive chelation for a limited duration. HYPERION, an open-label single-arm prospective phase 2 study, evaluated combination DFX-deferoxamine (DFO) in patient...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood
Autors principals: Aydinok, Yesim, Kattamis, Antonis, Cappellini, M. Domenica, El-Beshlawy, Amal, Origa, Raffaella, Elalfy, Mohsen, Kilinç, Yurdanur, Perrotta, Silverio, Karakas, Zeynep, Viprakasit, Vip, Habr, Dany, Constantinovici, Niculae, Shen, Junwu, Porter, John B.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2015
Matèries:
Clinical Trials and Observations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4490296/
https://ncbi.nlm.nih.gov/pubmed/25934475
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-07-586677
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars